Singapore markets closed

PAVmed Inc. (PAVM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6235+0.0034 (+0.55%)
At close: 04:00PM EST
0.6500 +0.03 (+4.25%)
Pre-market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.6201
Open0.6500
Bid0.0000 x 1400
Ask0.0000 x 1200
Day's range0.6200 - 0.6900
52-week range0.5800 - 3.4090
Volume1,178,651
Avg. volume684,332
Market cap58.425M
Beta (5Y monthly)0.69
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

    NEW YORK, December 08, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that the Company was selected as one of ten finalists for the Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry ("MD+DI"), a leading publication serving manufacturers of medical devices and in vitro diagnostics products,

  • Business Wire

    Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

    NEW YORK, December 01, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device ("EsoCheck") at the American Association for Cancer Research’s ("AACR") Special Conference: Precision Prevention, Early Detect

  • Business Wire

    PAVmed Provides Business Update and Third Quarter 2022 Financial Results

    NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.